18th Nov 2026 05:55
GSK PLC - London-based pharmaceutical company - US Food & Drug Administration grants accelerated approval to Nelkarmi, also known as neladalkib, for adults with previously-treated advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer. The approval was based on trial results that confirmed an overall response rate of 49% with a duration of response of six or more months in 76% of responders and 12 plus months in 52% of responders. The approval came before the original FDA target action date of November 27 and Nelkarmi previously received FDA's breakthrough therapy and orphan drug designations. Read More